Key result
Intravenous thrombolysis with recombinant tissue plasminogen activator in stroke patients taking dabigatran currently lacks data regarding bleeding risk.
No takes yet. Share an insight, caveat, or question.
This report discusses the use of intravenous rtPA in a stroke patient on dabigatran, an area where data on bleeding risk is lacking.
Smedt et al. (2010) studied this question. Intravenous thrombolysis with recombinant tissue plasminogen activator in stroke patients taking dabigatran currently lacks data regarding bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: